RE: lol great news not priced in and down goes..14 Apr 2021 10:36
I suspect PIs who want to ride the copper bull are switching to other investment opps with potentially more immediate returns - companies who are operators, or closer to operating. XTR is different story with AA buyout option but perhaps not all realise the story
Xenor - I'm sure I'm not saying anything you don't already know but I have had the same dilemna I felt I needed to place my bets to get best return on capital although crystallising the loss was painful. If those losses can be recovered with a return greater than the potential on RMM you should sit tight but that may be a tall order. If they can give a greater return then please let me know the details ;)
TBY you maybe correct on 6p and of course all depends on update and its content. This still is imho one of the better investment opps out there for Cu with a fairly limited downside . Anyway I'll monitor price a bit longer before taking the plunge for a further "final" top up. I keep reminding myself of Colins 1mil at 10p and the options at 10p. GAL
Oxford, UK - 6 April, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Group"), a leading gene and cell therapy group, announced today that it has signed a new three year Development & Supply Agreement ("DSA") with Boehringer Ingelheim for the manufacture and supply of various types of viral vectors. Under the terms of the DSA, Oxford Biomedica intends to manufacture GMP batches for Boehringer Ingelheim to support the development of viral vectors. The DSA also allows for the Group to manufacture and supply viral vector products in the future. John Dawson, Chief Executive Officer of Oxford Biomedica, said: "This Development and Supply Agreement with Boehringer Ingelheim demonstrates the good progress made in our partnership with Boehringer Ingelheim, which started in 2018. We are proud to be supporting another global pharmaceutical company in the development and manufacturing of their viral vector programs. "We now have a portfolio of partnerships spread across development of CAR-Ts, TCR-Ts and in vivo gene therapeutics, utilising lentiviral vectors. We are proud to partner with Boehringer Ingelheim, a business with proven excellence in complex manufacturing projects, as well as expertise in developing innovative medicines for patients with serious unmet medical needs."